Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.
Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. Saxon AJ, et al. Among authors: wiest k. Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6. doi: 10.1016/j.drugalcdep.2012.08.002. Epub 2012 Aug 22. Drug Alcohol Depend. 2013. PMID: 22921476 Free PMC article. Clinical Trial.
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W. Potter JS, et al. Among authors: wiest k. J Stud Alcohol Drugs. 2013 Jul;74(4):605-13. doi: 10.15288/jsad.2013.74.605. J Stud Alcohol Drugs. 2013. PMID: 23739025 Free PMC article. Clinical Trial.
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.
Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W. Teruya C, et al. Among authors: wiest k. J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743. J Psychoactive Drugs. 2014. PMID: 25364994 Free PMC article.
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. Ling W, et al. Among authors: wiest k. Addiction. 2016 Aug;111(8):1416-27. doi: 10.1111/add.13375. Epub 2016 Apr 21. Addiction. 2016. PMID: 26948856 Free PMC article. Clinical Trial.
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR. Gray KM, et al. Among authors: wiest k. Drug Alcohol Depend. 2017 Aug 1;177:249-257. doi: 10.1016/j.drugalcdep.2017.04.020. Epub 2017 Jun 10. Drug Alcohol Depend. 2017. PMID: 28623823 Free PMC article. Clinical Trial.
Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, Ghitza UE, Wahle A, Kim M, Shores-Wilson K, Sparenborg S, Coffin P, Schmitz J, Wiest K, Bart G, Sonne SC, Wakhlu S, Rush AJ, Nunes EV, Shoptaw S. Trivedi MH, et al. Among authors: wiest k. N Engl J Med. 2021 Jan 14;384(2):140-153. doi: 10.1056/NEJMoa2020214. N Engl J Med. 2021. PMID: 33497547 Free PMC article. Clinical Trial.
27 results